In this article, Gregory Vistnes outlines why Antitrust Agencies care about clinical integration, an issue that might seem primarily an issue of concern to the healthcare community and not antitrust enforcers, and how the agencies typically evaluate the competitive significance of clinical integration.
CRA Competition's response to EU Draft Merger Guidelines: An economic perspective on the emerging framework
Our European Competition team has contributed to the economic assessment in nearly a third of distinct merger decisions cited in the draft, (46 out of 164)...